Income Statement Presentation 2023

Spinal Muscular Atrophy: Evrysdi market leader in US and Japan Switches remain a key source of new patient starts YoY CER growth +59% Q4 update • >7,000 patients treated worldwide; retention rate in first 12 months of ~90% globally US: Growth driven by switch and naive patient starts including patients <2 months old • Ex-US: Continued strong growth and share gains in all major markets CHFM 400 350 300 250 +347% 200 150 100 50 0 Q4 20 Q4 21 Q4 22 . Continued growth and market share gains US Europe International Japan • EU: Label extension (<2 months old) based on Ph II (RAINBOWFISH) expected Outlook 2023 CER-Constant Exchange Rates; SMA-spinal muscular atrophy Roche 30

View entire presentation